Liraglutide also significantly decreased body weight (day 33); 4-h fasted plasma glucose concentration, triglyceride, and total cholesterol levels (day 28); insulin levels (day 34); hepatic microvesicular steatosis scores; and TNF-α content in HFCD-fed mice compared with vehicle, whereas teduglutide treatment had no significant effects on any of these end points. This evidence concerns the gene INS and steatosis.